The ACIP has recommended one dose of a pneumonia vaccine, the 23-valent pneumococcal polysaccharide vaccine, to seniors since 1997. Now, it is recommending that seniors receive PPSV23 as well as the 13-valent pneumococcal conjugate vaccine.
Pneumonia remains a major cause of death in seniors. Expanding the use of PCV13 to all adults, in addition to using the PPSV23 vaccine, should serve as added protection against pneumonia.
The ACIP did note that vaccinating adults with both vaccines “can be challenging because of complexities in the timing of the two vaccines, frequency, and intervals between doses.” The recommend practices, published in the Annals of Internal Medicine, provide a recommended schedule for when the doses should be administered based on patients’ age, health conditions and other factors.
More articles on vaccinations:
US pledges $800M to Global Alliance for Vaccines and Immunization
Low nursing home employee flu vaccination rates puts residents at risk
FDA approves meningococcal disease vaccine
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.